<DOC>
	<DOCNO>NCT02082197</DOCNO>
	<brief_summary>This open-study 26 week open label treatment period follow optional 26 week open label extension . The total treatment period 52 week .</brief_summary>
	<brief_title>An Efficacy Safety Study ABT-SLV176 Treatment Hypogonadal Men</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<criteria>Low testosterone Normal testosterone level Elevated Prostatic Specific Antigen ( PSA ) History breast prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>low testosterone</keyword>
</DOC>